Defence Therapeutics Announces Grant of Restricted Stock Units

Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) announced that its board approved a grant of 200,000 incentive restricted stock units (RSUs) to CEO and director Sebastien Plouffe, vesting immediately on April 24, 2026. Each RSU converts to one common share and expires April 24, 2027, subject to the Omnibus Incentive Plan and securities law hold periods.

News Market Reaction – DTCFF

+2.02%

+2.02% Session close to close

In the Apr 27 session, DTCFF gained 2.02%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the holder thereof to receive one common share of the Company expiring on April 24, 2027, subject to the terms of the Omnibus Incentive Plan of the Company and applicable securities law hold periods.

About Defence Therapeutics:

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum^® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.

For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294219

FAQ

How many RSUs did Defence Therapeutics (DTCFF) grant to CEO Sebastien Plouffe on April 24, 2026?

The company granted 200,000 RSUs to CEO Sebastien Plouffe. According to the company, the RSUs vest immediately and each unit converts to one common share, expiring on April 24, 2027 under the Omnibus Incentive Plan.

When do the 200,000 RSUs granted by Defence Therapeutics (DTCFF) vest and expire?

The RSUs vested immediately on April 24, 2026 and carry an expiry date of April 24, 2027. According to the company, conversion to common shares is subject to the Omnibus Incentive Plan and applicable securities law hold periods.

What does each restricted stock unit (RSU) from Defence Therapeutics (DTCFF) entitle the holder to receive?

Each RSU entitles the holder to receive one common share upon conversion. According to the company, RSU conversion is governed by the Omnibus Incentive Plan and subject to applicable securities law hold periods until transferability.

Does the Defence Therapeutics (DTCFF) RSU grant to the CEO create immediate share dilution?

The grant creates potential dilution if the RSUs convert to common shares prior to expiry. According to the company, 200,000 RSUs were issued and expire April 24, 2027; conversion depends on plan terms and applicable securities law hold periods.

What restrictions apply to the RSUs granted by Defence Therapeutics (DTCFF) to Sebastien Plouffe?

The RSUs are subject to the company's Omnibus Incentive Plan and applicable securities law hold periods. According to the company, the units vest immediately but remain governed by plan terms and legal holding restrictions until conversion or expiry on April 24, 2027.